All In Biotech

Drug Trial Radar · NCT05994690

CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients

An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients - a Study by the NOPHO-DB-SHIP Consortium, Master Protocol

Last checked: Nov 20, 2026Latest source record: Aug 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 905 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

905

Planned (sponsor's estimate)

Start

Jul 14, 2023

Primary completion

Mar 2031

Study completion Dec 2035

Sponsor

Lead sponsor
Princess Maxima Center for Pediatric OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
European Commission
First posted
Aug 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 day, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The CHIP-AML22 Master protocol has the overall aim of increasing the cure rate in newly diagnosed pediatric de novo AML patients, while avoiding unnecessary toxicity.

Conditions

  • Acute Myeloid Leukemia in Children

Interventions

  • Standard Intervention RcDrug

    3 consolidation courses (HAM + HA3E + FLA)

  • Investigational Intervention RcDrug

    2 consolidation courses (HAM + FLA)

  • Standard Intervention RiDrug

    No addition of GO to first induction course

  • Investigational Intervention RiDrug

    Addition of GO to first induction course

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overarching primary objectiveTime frame: 5 years
  2. Primary objective Randomisation ConsolidationTime frame: 5 years
  3. Primary objective Randomisation InductionTime frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Princess Máxima Center for pediatric oncology

    Utrecht, Utrecht, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.